Monoclonal antibodies (mAbs) have emerged as important therapeutics for the treatment of life-threatening diseases. The successes of mAbs have triggered the development of various next generation formats. In oncology, antibody-drug conjugates (ADCs) are particularly promising, since they synergistically combine a specific mAb linked to a biologically active cytotoxic drug via a stable linker. The promise of ADCs is that highly toxic drugs can selectively be delivered to tumor cells thereby substantially lowering side effects as typically experienced with classical chemotherapy.
Monoclonal antibodies have a complexity far exceeding that of small molecule drugs, hence, unraveling this complexity represents an analytical challenge. This challenge becomes even bigger in case ADCs are considered since the heterogeneity of the initial antibody is superimposed with the variability associated with the cytotoxic drug conjugation strategy. The present webinar will highlight the power of two dimensional liquid chromatography in hyphenation to high resolution mass spectrometry for the characterization of monoclonal antibodies and antibody-drug conjugates. Both multiple heart-cutting LC-LC, applied at protein level, and comprehensive LCxLC, applied at peptide level, will be discussed.
For Research Use Only. Not for use in diagnostic procedures.
- Obtain insight in the complexity associated with monoclonal antibodies and antibody-drug conjugates.
- Learn about the challenges and strategies associated with the characterization of monoclonal antibodies and antibody-drug conjugates.
- Learn about the different modes of two dimensional liquid chromatography and its hyphenation to mass spectrometry.